Anne Pradines

Toulouse, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

Technical recommendations from a large-scale French Delphi consensus: A step toward European harmonization of ctDNA analysis.

Technical recommendations from a large-scale French Delphi consensus: A step toward European harmonization of ctDNA analysis.

Journal: European journal of cancer (Oxford, England : 1990)
Published: March 19, 2026

GFCO national recommendations on the use of liquid biopsy for circulating tumor DNA analysis in oncology

GFCO national recommendations on the use of liquid biopsy for circulating tumor DNA analysis in oncology

Journal: Bulletin du cancer
Published: December 10, 2025

Detection of EGFR mutations at pM concentration in ten minutes using a microfluidic concentration and separation module.

Detection of EGFR mutations at pM concentration in ten minutes using a microfluidic concentration and separation module.

Journal: Biomedical microdevices
Published: July 15, 2025

Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane.

Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane.

Journal: International journal of cancer
Published: November 14, 2024

Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.

Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 03, 2024

Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients.

Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients.

Journal: Scientific reports
Published: May 21, 2024

Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies.

Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies.

Journal: Nature communications
Published: March 02, 2024

Transcriptomics profiling of the non-small cell lung cancer microenvironment across disease stages reveals dual immune cell-type behaviors.

Transcriptomics profiling of the non-small cell lung cancer microenvironment across disease stages reveals dual immune cell-type behaviors.

Journal: Frontiers in immunology
Published: March 02, 2024

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

Journal: The Lancet. Oncology
Published: June 07, 2022

Epigenetically regulated PCDHB15 impairs aggressiveness of metastatic melanoma cells.

Epigenetically regulated PCDHB15 impairs aggressiveness of metastatic melanoma cells.

Journal: Clinical epigenetics
Published: June 06, 2022

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer.

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer.

Journal: Cancers
Published: April 19, 2022

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.

Journal: BMJ open
Published: March 04, 2022
Showing 1-12 of 37

Last Updated: 09/26/2026